L-Dopa therapy increases homocysteine concentration in cerebrospinal fluid from patients with Parkinson's disease

Journal of Clinical Neuroscience

Volumn 17, Issue 6, 2010, Pages 717-721

  Isobe, Chiaki ^a,b   Abe, Takashi ^b   Terayama, Yasuo ^b  

^a IWATE MEDICAL UNIVERSITY   (Japan)

^b Chitose Daiichi Hospital   (Japan)

Author keywords

Cerebrospinal fluid; Free homocysteine; L Dopa; Oxidative stress; Parkinson's disease; Total homocysteine

Indexed keywords

HOMOCYSTEINE; LEVODOPA; METHIONINE;

ADULT; AMINO ACID SYNTHESIS; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CLINICAL EVALUATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HUMAN TISSUE; MALE; METHYLATION; OUTCOME ASSESSMENT; PARKINSON DISEASE; PRIORITY JOURNAL; TREATMENT RESPONSE;

AGED; ANTIPARKINSON AGENTS; CASE-CONTROL STUDIES; FEMALE; HOMOCYSTEINE; HUMANS; LEVODOPA; MALE; METHIONINE; MIDDLE AGED; PARKINSON DISEASE; STATISTICS, NONPARAMETRIC;

EID: 77953130994     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocn.2009.09.034     Document Type: Article

References (25)

1. Edwards T.M., and Myers J.P. Environmental exposures and gene regulation in disease etiology. Cien Saude Colet 13 (2008) 269-281
2. Nishinaga M., Ozawa T., and Shimada K. Homocysteine, a thrombogenic agent, suppresses anticoagulant heparin sulfate expression in cultured porcine aortic endothelial cells. J Clin Invest 92 (1993) 1381-1386
3. Starkebaum G., and Harian J.M. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 77 (1986) 1370-1376
4. Ueland P.M. Homocysteine species as components of plasma redox thiol status. Clin Chem 41 (1995) 340-342
5. Welch G.N., and Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 338 (1998) 1042-1050
6. Frosst P., Blom H.J., Milos R., et al. A candidate genetic risk factor for vascular disease: a common mutation in methylentetrahydrofolate reductase. Nat Genet 10 (1995) 111-113
7. Joosten E., Lesaffre E., Riezler R., et al. Is metabolic evidence for vitamin B-12 and folate deficiency more frequent in elderly patients with Alzheimer's disease?. J Gerontol 252 (1997) 76-79
8. Nygard O., Vollset S.E., Refsum H., et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA 274 (1995) 1526-1533
9. Lehmann M., Gottfries C.G., and Regland B. Identification of cognitive impairment in the elderly: homocysteine is an early marker. Dement Geriatr Cogn Disord 10 (1999) 12-20
10. Kruman I.I., Kumaravel T.S., Lohani A., et al. Folic acid deficiency and homocysteine impair DNA in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer's disease. J Neurosci 22 (2002) 1752-1762
11. Isobe C., Abe T., Kikuchi T., et al. Cabergoline scavenges peroxynitrite enhanced by L-DOPA therapy in patients with Parkinson's disease. Eur J Neurol 13 (2006) 346-350
12. Hughes A.J., Daniel S.E., Kifford L., et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55 (1992) 181-184
13. Allain P., Bouil A.L., Cordillet E., et al. Sulphate and cysteine levels in the plasma of patients with Parkinson's disease. Neurotoxicol 16 (1995) 527-530
14. Kuhn W., Roebroek R., Blom H., et al. Hyperhomocysteinaemia in Parkinson's disease. J Neurol 32 (1998) 811-812
15. Müller T., Werne B., Fowler B., et al. Nigral endothelial dysfunction, homocysteine, and Parkinson's disease. Lancet 354 (1999) 126-127
16. Berg D., and Hochstrasser H. Iron metabolism in Parkinsonian syndromes. Mov Disord 21 (2006) 1299-1310
17. Kundu S., Kumar M., Sen U., et al. Nitrotyrosinylation, remodeling and endothelial-myocyte uncoupling in iNOS, cystathionine beta synthase (CBS) knockouts and iNOS/CBS double knockout mice. J Cell Biochem 106 (2009) 119-126
18. Wenzhem D., Bruce L., Cutler R.G., et al. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J Neurochem 80 (2002) 101-110
19. Yasui K, Kowa H, Nakaso K, et al. Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology 2000;55:437-40.
20. Takeshima T., Shimoda K., Johnston J.M., et al. Standardized methods to bioassay neurotrophic factors for dopaminergic neurons. J Neurosci Methods 67 (1996) 27-41
21. Isobe C., Murata T., Sato C., et al. Increased of total homocysteine concentration in cerebrospinal fluid in patients with Alzheimer's disease and Parkinson's disease. Life Sci 77 (2005) 1836-1843
22. Zhao W.Q., Latinwo L., Liu X.X., et al. L-dopa upregulates the expression and activities of methionine adenosyl-transferase and catechol-O-methyltransferase. Exp Neurol 171 (2001) 127-138
23. Parnetti L., Bottigliert T., Lowenthal D., et al. Role of homocysteine in age-related vascular and non-vascular disease. Aging (Milano) 9 (1997) 241-257
24. Rantan R.R., Murphy T.H., and Baraban J.M. Macromolecular synthesis inhibitors prevent oxidative stress-induced apoptosis in embryonic cortical neurons by shunting cysteine from protein synthesis to glutathione. J Neurosci 14 (1994) 4385-4392
25. Faucheux B.A., Bonner A.M., Agid Y., et al. Blood vessels change in the mesencephalon of patients with Parkinson's disease. Lancet 353 (1999) 981-982